Sucampo forms holding company to improve efficiency
This article was originally published in Scrip
Sucampo Pharmaceuticals is to set itself up with a holding company to provide a more efficient corporate structure. After the changes, Sucampo Pharmaceuticals Inc will be the public company, with three wholly owned subsidiaries: Sucampo Pharma Ltd based in Tokyo and Osaka; Sucampo Pharma Americas Inc, based in Bethesda; andSucampo Pharma Europe, based in Oxford, UK, and Basel, Switzerland. Dr Sachiko Kuno, a co-founder of the company and a former CEO, will rejoin the board on completion of the changes. The company will also undertake a stock buyback of up to $10 million, and has promoted its acting chief financial officer, Jan Smilek, to CFO.
You may also be interested in...
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.